MYD88 and diffuse large B-cell lymphoma: On pooled analysis of 40 studies, including 2736 DLBCL patients, the overall prevalence rate of MYD88 L265P mutation was 29.0% [95% confidence interval (CI): 17.2–44.5%] (Table 1)2–41.